Gastrin I (human): Enabling Advanced GI Physiology Modeling in Organoid Systems

Introduction

Gastrin I (human), an endogenous regulatory peptide, is a cornerstone for elucidating the mechanisms underlying gastric acid secretion and gastrointestinal (GI) physiology. As research models shift toward physiologically relevant in vitro systems, such as organoids derived from human pluripotent stem cells, the precise manipulation of receptor-mediated signaling pathways becomes essential. This article explores the unique capabilities of Gastrin I (human) in contemporary GI physiology studies—particularly in the context of organoid models—and contrasts its role and research applications with prior literature.

Gastrin I (human): Structure, Function, and Technical Characteristics

Gastrin I (human) (CAS 10047-33-3), with a molecular weight of 2098.22 Da, is a peptide hormone produced primarily by G cells in the gastric antrum. Functionally, it acts as a potent gastric acid secretion regulator by engaging the cholecystokinin B (CCK2) receptor (also known as the gastrin receptor), a G protein-coupled receptor (GPCR) expressed on gastric parietal cells. Upon binding, Gastrin I triggers CCK2 receptor signaling cascades that modulate intracellular calcium influx and activate the H⁺/K⁺ ATPase (proton pump), directly increasing acid secretion in the stomach. The specificity and purity of commercially available Gastrin I (human)—supplied as a lyophilized powder, insoluble in water and ethanol but readily dissolved in DMSO (≥21 mg/mL)—make it an indispensable tool for dissecting receptor-mediated signal transduction in vitro. Quality control analysis by HPLC and mass spectrometry ensures ≥98% purity, critical for reproducibility and data integrity in advanced research settings.

Integrating Gastrin I (human) in Organoid-Based GI Physiology Studies

The emergence of human pluripotent stem cell (hPSC)-derived intestinal organoids marks a pivotal advancement in modeling GI physiology and disease. Unlike traditional cell lines or animal models, organoids possess self-renewing and multi-lineage differentiation capacities, closely recapitulating the architecture and function of native tissue. This fidelity is particularly valuable for pharmacokinetic, absorption, and signal transduction studies, as highlighted by Saito et al. (European Journal of Cell Biology, 2025), who demonstrated that hiPSC-derived intestinal organoids (iPSC-IOs) can differentiate into mature enterocytes expressing drug-metabolizing enzymes and transporters relevant to human physiology.

Within this context, Gastrin I (human) serves as a precise agonist for CCK2 receptor signaling, enabling researchers to interrogate the downstream effects of receptor activation in organoid models. By adding Gastrin I to organoid cultures, it is possible to:

• Stimulate gastric acid secretion pathways and assess the functional competency of parietal cell-like populations within the organoid.
• Probe the regulation and dynamics of proton pump activation in response to physiologically relevant stimuli.
• Model disease states associated with hyper- or hypo-gastrinemia, facilitating the evaluation of candidate therapeutic interventions in a controlled, human-relevant system.

Moreover, combining Gastrin I-driven stimulation with advanced readouts—such as reporter assays, single-cell RNA sequencing, and live imaging—affords unprecedented resolution for dissecting CCK2 receptor-mediated signal transduction networks within complex 3D tissue environments.

Gastrin I (human) in Gastrointestinal Disorder Research

Dysregulation of gastric acid secretion is implicated in a spectrum of gastrointestinal disorders, including peptic ulcer disease, Zollinger-Ellison syndrome, and certain forms of gastric cancer. As a result, the ability to model and manipulate these pathways in vitro is invaluable. Gastrin I (human) enables researchers to:

• Recapitulate disease-relevant signaling by overactivating or inhibiting the CCK2 receptor axis in organoid or monolayer cultures.
• Evaluate the efficacy and mechanistic impact of pharmacological agents targeting the gastrin–CCK2 receptor–proton pump axis.
• Dissect feedback regulation and cross-talk between gastrin signaling, cellular differentiation, and barrier function within the GI epithelium.

By leveraging the high purity and reproducibility of Gastrin I (human), studies can be designed with stringent dose-response controls, enabling the quantification of functional outcomes—such as acid release, parietal cell activation, or gene expression changes—under defined experimental conditions.

Technical Guidance for Experimental Design

For optimal use in gastric acid secretion pathway research, Gastrin I (human) should be handled with care to preserve bioactivity:

• Reconstitute in DMSO at ≥21 mg/mL; avoid water or ethanol due to insolubility.
• Aliquot and store desiccated at -20°C; minimize freeze-thaw cycles.
• Prepare working solutions immediately prior to use, as long-term storage of solutions is not recommended.
• Confirm receptor expression and signaling competency in organoid or cell line models prior to stimulation, e.g., via qRT-PCR or immunostaining for CCK2 receptor.
• Employ appropriate controls (vehicle, receptor antagonists) to distinguish specific versus off-target effects.

These best practices are essential for ensuring data reliability, particularly when integrating Gastrin I stimulation with complex organoid systems or high-content analytical platforms.

Expanding the Toolkit: Synergistic Approaches and Future Directions

The versatility of Gastrin I (human) as a CCK2 receptor agonist extends beyond gastric acid secretion studies. In advanced GI physiology studies, it can be used synergistically with other pathway modulators—such as Wnt agonists (e.g., R-spondin1) and EGF—to fine-tune epithelial maturation and functional differentiation in organoid cultures. This combinatorial approach mirrors the complex interplay of signals in vivo and enhances the physiological relevance of in vitro models.

Emerging single-cell and spatial transcriptomics technologies present opportunities to map the heterogeneity of CCK2 receptor signaling responses within organoids. By combining targeted Gastrin I stimulation with these technologies, researchers can uncover cell-type-specific effects and network interactions critical for understanding GI health and disease.

Conclusion

As the field moves toward more sophisticated models of human GI physiology, Gastrin I (human) stands out as a rigorously characterized, high-purity reagent for probing gastric acid secretion, proton pump activation, and receptor-mediated signaling in organoid systems. Its use enables mechanistic studies of disease, drug action, and tissue homeostasis that are not possible with animal models or conventional cell lines alone. In contrast to prior works—such as 'Gastrin I (human): Applications in Organoid and GI Physiology', which primarily cataloged applications—this article focuses on integrating Gastrin I with organoid-based pharmacokinetic and signal transduction studies, drawing on recent advances documented by Saito et al. (2025). By synthesizing technical, methodological, and scientific perspectives, this work offers novel guidance for researchers aiming to leverage Gastrin I (human) in next-generation models of gastrointestinal physiology and disease.